Scholars Central

Conference abstractPublished 1 Apr 2016

Atrial fibrillation & chronic kidney disease: focus on rivaroxaban

Authors: Jose Luis Gorriz

University of Valencia, Spain

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Renal insufficiency increases the risk of stroke and bleeding in atrial fibrillation patients. Although vitamin K antagonists reduce the risk of stroke in patients with moderate renal dysfunction, this observation is less clear in patients with renal impairment. Moreover, the risk of bleeding with vitamin K antagonists increases as renal function worsens. Maintaining international normalized ratio values within therapeutic targets is more difficult in patients with renal dysfunction, and those agents may cause warfarin-related nephropathy and vascular calcification. Rivaroxaban is the only nonvitamin K oral anticoagulant with a dose specifically tested in patients with moderate renal insufficiency. Rivaroxaban is effective for the prevention of stroke in atrial fibrillation patients with moderate renal dysfunction, with a lower risk of intracranial and fatal bleeding. Key words: Atrial fibrillation , chronic kidney disease , new oral anticoagulant, nonvitamin K oral anticoagulant , renal function , renal insufficiency , rivaroxaban, vitamin K antagonist.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Jose Luis Gorriz”